Bladder Cancer

First positive Phase 3 trial shows perioperative immunotherapy combination addresses critical gap for cisplatin-ineligible patients.

32% risk reduction in high-risk bladder cancer with sasanlimab-BCG combo—first treatment advance in 30+ years...

FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in...

Ideaya presents promising data across three cancer drugs: darovasertib (76% response), IDE849 (58% response), and...

New drug-releasing system, TAR-200, eliminated tumors in 82% of patients in phase 2 clinical trial...

HMGA2 protein overexpressed in 70% of bladder cancer tissues, correlating with tumor stage, grade, and...

TMT was not cost-effective at 5-year (ICER, $464,291 per QALY) or 10-year (ICER, $308,638 per...

IMvigor011 trial shows Signatera ctDNA test predicts which bladder cancer patients benefit from adjuvant atezolizumab...

Split-dose cisplatin + atezolizumab achieved 48.5% response rate in cisplatin-ineligible urothelial carcinoma patients with manageable...

First systemic therapy to improve survival when used before/after surgery for MIBC patients ineligible for...

XBCM urinary biomarker reduces cystoscopies by 55% in high-grade NMIBC surveillance without compromising recurrence detection...

Researchers identified six plant-derived flavonoids toxic to bladder cancer cells using innovative Cell Painting microscopy...

Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal...

FDA approves mitomycin (Zusduri) for recurrent low-grade NMIBC: 78% complete response, 79% maintain response ≥12...

CR rates greater than 80% achieved with TAR-200 device - first time we've seen rates...

XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV while reducing cystoscopy burden by...